Pharmacotherapy strategies for treatment-resistant depression

Journal of Psychosocial Nursing and Mental Health Services

Volumn 44, Issue 11, 2006, Pages 11-14

  Howland, Robert H ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33845339294     PISSN: 02793695     EISSN: None     Source Type: Journal    
DOI: 10.3928/02793695-20061101-02     Document Type: Review

References (18)

1. Fava, M., Rush, A.J., Wisniewski, S.R., Nierenberg, A.A., Alpert, J.E., McGrath, P.J., et al. (2006). A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments fur depressed outpatients: A STAR*D report. American Journal of Psychiatry, 163, 1161-1172.
2. Rowland, R.H. (199.3). Thyroid dysfunction in refractory depression: Implications for pathophysiology and treatment. Journal of Clinical Psychiatry, 54, 47-54.
3. Howland, R.H. (2006). Transdermal selegiline: A novel MAOl formulation for depression. Journal of Psychosociol Nursing and Mental Health Services, 44(7), 9-12.
4. Howland, R.H., & Thase, M.E. (1997). Switching strategies for the treatment of unipolar major depression. In A.J. Rush (Ed.), Mood disorders: Systematic medication management: Vol. 25. Modern problems of pharmacopsychiatry (pp. 56-65). Basel, Switzerland: S. Karger AG.
5. Howland, R.H., & Thase, M.E. (1999). What to do with SSRI nonresponders? Journal of Practical Psychiatry ana Behavioral Health, 5, 216-223.
6. Howland, R.H., & Thase, M.E. (2002). Mood disorders: Therapeutic armamentarium. In H. D"haenen, J.A. den Boer, & P. Willnet (Eds.), Biological psychiatry (pp. 861-875). London, UK: Wiley & Sons.
7. McGrath, P.J., Stewart, J.W., Fava, M., Trivedi, M.H., Wisniewski, S.R., Nierenberg, A.A., et al. (2006). Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: A STAR*D report. American Journal of Psychiatry, 163, 1531-1541.
8. Nierenberg, A.A., Fava, M., Trivedi, M.H., Wisniewski, S.R., Thase, M.E., McGrath, P.J., et al. (2006a). A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: A STAR*D report. American Journal of Psychiatry, 163, 1519-1530.
9. Nierenberg, A.A., Ostacher, M.J., Calabrese, J.R., Ketter, T.A., Marangell, L.B., Miklowitz, D.J., et al. (2006b). Treatmentresistant bipolar depression: A STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Americon Journal of Psychiatry, 163, 210-216.
10. Rush, A.J., Fava, M., Wisniewski, S.R., Lavori, P.W., Trivedi, M.H., Sackeim, H.A., et al., for the STAR*D Investigators Group. (2004). Sequenced treatment alternatives to relieve depression (STAR*D); Rationale and design. Controlled Clinical Trials, 25, 119-142.
11. Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Stewart, J.W., Nierenberg, A.A., Thase, M.E., et al., for the STAR*D Study Team. (2006). Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. New England Journal of Medicine, 354, 1231-1242.
12. Thase, M.E. (2005). Pharmacologic strategies for treatment-resistant depression. Psychiatric Annals, 35, 970-978.
13. Thase, M.E., Friedman, E.S., & Howland, R.H. (2000). Venlafaxine and treatment-resistant depression. Depression and Anxiety, 12(Suppl. 1), 55-62.
14. Thase, M.E., Howland, R.H., & Friedman, E.S, (1998). Treating antidepressant nonresponders with augmentation strategies: An overview. Journal of Clinical Psychiatry, 59(Suppl. 5), 5-12.
15. Trivedi, M.H., Fava, M., Wisniewski, S.R., Thase, M.E., Quitkin, F., Warden, D., et al., for the STAR*D Study Team. (2006a). Medication augmentation after the failure of SSRIs for depression. New England Journal of Medicine, 354, 1243-1252.
16. Trivedi, M.H., Rush, A.J., Wisniewski, S.R., Nierenberg, A.A., Warden, D., Ritz, L., et al., for the STAR*D Study Team. (2006b). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. American Journal of Psychiatry, 163, 28-40.
17. Valenstein, M., McCarthy, J.F., Austin, K.L., Greden, J.F., Young, E.A., & Blow, EC. (2006). What happened to lithium? Antidepressant augmentation in clinical settings. American Journal of Psychiatry, 163, 1219-1225.
18. Zajecka, J., & Goldstein, C. (2005). Combining and augmenting: Choosing the right therapies for treatment-resistant depression. Psychiatric Annals, 35, 993-1000.